Biomarker discovery offers hope for aggressive breast cancer treatment

Cor­cept Ther­a­peu­tics lost its patent in­fringe­ment law­suit against Te­va Phar­ma­ceu­ti­cals over its Cush­ing’s syn­drome drug Ko­r­lym af­ter a New Jer­sey judge ruled in Te­va’s fa­vor.

Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings